Posted in:News Lilly Announces Positive Results for Galcanezumab in Treating Episodic Cluster Headaches By Seth Cockrum May 25, 2018 Comments are off Last week, Eli Lilly and Company (“Lilly”) announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with... Read more Tagged with: Aimovig™, Alder Biopharmaceuticals, Amgen, Eli Lilly, eptinezumab, erenumab, FDA, fremanezumab, galcanezumab, News, Novartis, Teva http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Novartis and Amgen Announce FDA Approval of Aimovig™ By Seth Cockrum May 23, 2018 Comments are off Last week, Novartis and Amgen announced the FDA approved Aimovig™ (erenumab) for the preventive treatment of migraine in adults. The... Read more Tagged with: Aimovig™, Alder Biopharmaceuticals, Amgen, Eli Lilly, erenumab, FDA, Novartis, Teva http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus